Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAKEN study of LY3473329 in adults with elevated lipoprotein(a) at high cardiovascular risk
NL-OMON59248Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of muvalaplin in dyslipidemia and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in lipoprotein(a). Started Mar 2023; status: completed.
02
Drugs
muvalaplin
03
Conditions
dyslipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON59248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59248.